It's because of the stem cells.
Cornell University researchers determined that for testicular cancer, those cells are more capable of responding to chemotherapy, and they do so better than stem cells in other forms of cancer. And this effectiveness takes place with testicular cancer even after it metastasizes.
"We conclude that the chemosensitivity of TGCTs," or testicular germ cell tumors, the authors wrote in their study, "derives from the sensitivity of their cancer stem cells to DNA-damaging chemotherapy." The paper was published Tuesday in the journal Cell Reports.
Additionally, the findings, which used mouse models, are significant because determining why these...